The Role of CD36 in Cancer Progression and Its Value As a Therapeutic Target

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Jun 28

PMID 37371076

Authors

William W Feng

Hannah T Zuppe

Manabu Kurokawa

Affiliations

Soon will be listed here.

Abstract

Cluster of differentiation 36 (CD36) is a cell surface scavenger receptor that plays critical roles in many different types of cancer, notably breast, brain, and ovarian cancers. While it is arguably most well-known for its fatty acid uptake functions, it is also involved in regulating cellular adhesion, immune response, and apoptosis depending on the cellular and environmental contexts. Here, we discuss the multifaceted role of CD36 in cancer biology, such as its role in mediating metastasis, drug resistance, and immune evasion to showcase its potential as a therapeutic target. We will also review existing approaches to targeting CD36 in pre-clinical studies, as well as discuss the only CD36-targeting drug to advance to late-stage clinical trials, VT1021. Given the roles of CD36 in the etiology of metabolic disorders, such as atherosclerosis, diabetes, and non-alcoholic fatty liver disease, the clinical implications of CD36-targeted therapy are wide-reaching, even beyond cancer.

Citing Articles

Prognostic significance and immune microenvironment infiltration patterns of hypoxia and endoplasmic reticulum stress-related genes in gastric cancer.

Li L, Liang Y, Xu W Front Oncol. 2025; 15:1542740.

PMID: 40061897 PMC: 11885130. DOI: 10.3389/fonc.2025.1542740.

Discovery and characterization of a human anti-CD36 scFv.

Mata-Cruz C, Guerrero-Rodriguez S, Gomez-Castellano K, Carballo-Uicab G, Almagro J, Perez-Tapia S Front Immunol. 2025; 16:1531171.

PMID: 39967671 PMC: 11832482. DOI: 10.3389/fimmu.2025.1531171.

CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells.

Liu Y, Huang W, Wang S, Hsu H, Kao T, Chung W Cancer Metab. 2025; 13(1):6.

PMID: 39920872 PMC: 11806886. DOI: 10.1186/s40170-025-00375-5.

Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma.

Poenaru R, Milanesi E, Niculae A, Dobre A, Vladut C, Ciocirlan M World J Gastrointest Oncol. 2025; 17(1):98409.

PMID: 39817147 PMC: 11664611. DOI: 10.4251/wjgo.v17.i1.98409.

Monocyte-cancer cell fusion is mediated by phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation.

Shabo I, Midtbo K, Branstrom R, Lindstrom A PLoS One. 2025; 20(1):e0311027.

PMID: 39752516 PMC: 11698428. DOI: 10.1371/journal.pone.0311027.

References

Deng M, Cai X, Long L, Xie L, Ma H, Zhou Y . CD36 promotes the epithelial-mesenchymal transition and metastasis in cervical cancer by interacting with TGF-β. J Transl Med. 2019; 17(1):352. PMC: 6815430. DOI: 10.1186/s12967-019-2098-6. View

Nath A, Chan C . Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci Rep. 2016; 6:18669. PMC: 4698658. DOI: 10.1038/srep18669. View

Yamashita S, Hirano K, Kuwasako T, Janabi M, Toyama Y, Ishigami M . Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem. 2006; 299(1-2):19-22. DOI: 10.1007/s11010-005-9031-4. View

Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P . Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib. Int J Oncol. 2021; 58(2):238-250. DOI: 10.3892/ijo.2020.5163. View

Yao C, Fowle-Grider R, Mahieu N, Liu G, Chen Y, Wang R . Exogenous Fatty Acids Are the Preferred Source of Membrane Lipids in Proliferating Fibroblasts. Cell Chem Biol. 2016; 23(4):483-93. PMC: 5510604. DOI: 10.1016/j.chembiol.2016.03.007. View

Volpert O, Zaichuk T, Zhou W, Reiher F, Ferguson T, Stuart P . Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med. 2002; 8(4):349-57. DOI: 10.1038/nm0402-349. View

Bujold K, Mellal K, Zoccal K, Rhainds D, Brissette L, Febbraio M . EP 80317, a CD36 selective ligand, promotes reverse cholesterol transport in apolipoprotein E-deficient mice. Atherosclerosis. 2013; 229(2):408-14. DOI: 10.1016/j.atherosclerosis.2013.05.031. View

Yuan J, Lugea A, Zheng L, Gukovsky I, Edderkaoui M, Rozengurt E . Protein kinase D1 mediates NF-kappaB activation induced by cholecystokinin and cholinergic signaling in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol. 2008; 295(6):G1190-201. PMC: 2604803. DOI: 10.1152/ajpgi.90452.2008. View

Nicholls H, Kowalski G, Kennedy D, Risis S, Zaffino L, Watson N . Hematopoietic cell-restricted deletion of CD36 reduces high-fat diet-induced macrophage infiltration and improves insulin signaling in adipose tissue. Diabetes. 2011; 60(4):1100-10. PMC: 3064084. DOI: 10.2337/db10-1353. View

10.

Hao J, Wang J, Guo H, Zhao Y, Sun H, Li Y . CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020; 11(1):4765. PMC: 7505845. DOI: 10.1038/s41467-020-18565-8. View

11.

Tandon N, Lipsky R, Burgess W, Jamieson G . Isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem. 1989; 264(13):7570-5. View

12.

Asch A, Barnwell J, Silverstein R, Nachman R . Isolation of the thrombospondin membrane receptor. J Clin Invest. 1987; 79(4):1054-61. PMC: 424283. DOI: 10.1172/JCI112918. View

13.

Watt M, Clark A, Selth L, Haynes V, Lister N, Rebello R . Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11(478). DOI: 10.1126/scitranslmed.aau5758. View

14.

Jayawardhana A, Stilgenbauer M, Datta P, Qiu Z, Mckenzie S, Wang H . Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36. Chem Commun (Camb). 2020; 56(73):10706-10709. DOI: 10.1039/d0cc02174a. View

15.

Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M . Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. 2016; 19(1):23-37. PMC: 4938766. DOI: 10.1016/j.stem.2016.06.001. View

16.

Feng W, Wilkins O, Bang S, Ung M, Li J, An J . CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. Cell Rep. 2019; 29(11):3405-3420.e5. PMC: 6938262. DOI: 10.1016/j.celrep.2019.11.008. View

17.

Harikumar K, Kunnumakkara A, Ochi N, Tong Z, Deorukhkar A, Sung B . A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010; 9(5):1136-46. PMC: 2905628. DOI: 10.1158/1535-7163.MCT-09-1145. View

18.

Guthmann F, Maehl P, Preiss J, Kolleck I, Rustow B . Ectoprotein kinase-mediated phosphorylation of FAT/CD36 regulates palmitate uptake by human platelets. Cell Mol Life Sci. 2003; 59(11):1999-2003. PMC: 11337428. DOI: 10.1007/pl00012522. View

19.

Kuda O, Pietka T, Demianova Z, Kudova E, Cvacka J, Kopecky J . Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages. J Biol Chem. 2013; 288(22):15547-55. PMC: 3668716. DOI: 10.1074/jbc.M113.473298. View

20.

van Oort M, Drost R, JanBen L, Van Doorn J, Kerver J, Van der Horst D . Each of the four intracellular cysteines of CD36 is essential for insulin- or AMP-activated protein kinase-induced CD36 translocation. Arch Physiol Biochem. 2014; 120(1):40-9. DOI: 10.3109/13813455.2013.876049. View